Cargando…
Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma
BACKGROUND: Thymoma and thymic carcinoma are rare thymic epithelial tumors. We investigated the efficacy of first‐line gemcitabine and cisplatin (GP) chemotherapy versus gemcitabine and cisplatin chemotherapy combined with the anti‐angiogenic drug endostar (GP + E) in advanced thymoma and thymic car...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312837/ https://www.ncbi.nlm.nih.gov/pubmed/30411854 http://dx.doi.org/10.1111/1759-7714.12891 |
_version_ | 1783383832753340416 |
---|---|
author | Wang, Yang Nie, Jun Dai, Ling Hu, Weiheng Chen, Xiaoling Han, Jindi Ma, Xiangjuan Tian, Guangming Han, Sen Long, Jieran Zhang, Ziran Fang, Jian |
author_facet | Wang, Yang Nie, Jun Dai, Ling Hu, Weiheng Chen, Xiaoling Han, Jindi Ma, Xiangjuan Tian, Guangming Han, Sen Long, Jieran Zhang, Ziran Fang, Jian |
author_sort | Wang, Yang |
collection | PubMed |
description | BACKGROUND: Thymoma and thymic carcinoma are rare thymic epithelial tumors. We investigated the efficacy of first‐line gemcitabine and cisplatin (GP) chemotherapy versus gemcitabine and cisplatin chemotherapy combined with the anti‐angiogenic drug endostar (GP + E) in advanced thymoma and thymic carcinoma. METHODS: The records of 45 patients with invasive metastatic thymomas or thymic carcinomas treated with GP as first‐line therapy between August 2008 and July 2017 at the Department of Respiratory Medicine, Peking University Cancer Hospital and Institute were retrospectively reviewed. RESULTS: Eighteen patients (75%) in the GP + E group achieved a partial response and six (25%) had stable disease. In GP only group, nine (42.8%) patients achieved a partial response, 11 (52.4%) had stable disease, and one (4.8%) had progressive disease. The GP + E group had a significantly higher overall response rate (75% vs. 42.9%; P = 0.028), and median progression‐free survival (PFS) and overall survival (OS) of 19 and 76 months, respectively. In the GP only group, median PFS and OS were 16 and 29 months, respectively. PFS and OS were not significantly different between the groups. CONCLUSIONS: GP has moderate efficacy and could represent a suitable first‐line therapy for thymic carcinoma and thymoma. Chemotherapy combined with endostar could improve the overall response rate, but did not prolong PFS or OS. |
format | Online Article Text |
id | pubmed-6312837 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-63128372019-01-07 Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma Wang, Yang Nie, Jun Dai, Ling Hu, Weiheng Chen, Xiaoling Han, Jindi Ma, Xiangjuan Tian, Guangming Han, Sen Long, Jieran Zhang, Ziran Fang, Jian Thorac Cancer Original Articles BACKGROUND: Thymoma and thymic carcinoma are rare thymic epithelial tumors. We investigated the efficacy of first‐line gemcitabine and cisplatin (GP) chemotherapy versus gemcitabine and cisplatin chemotherapy combined with the anti‐angiogenic drug endostar (GP + E) in advanced thymoma and thymic carcinoma. METHODS: The records of 45 patients with invasive metastatic thymomas or thymic carcinomas treated with GP as first‐line therapy between August 2008 and July 2017 at the Department of Respiratory Medicine, Peking University Cancer Hospital and Institute were retrospectively reviewed. RESULTS: Eighteen patients (75%) in the GP + E group achieved a partial response and six (25%) had stable disease. In GP only group, nine (42.8%) patients achieved a partial response, 11 (52.4%) had stable disease, and one (4.8%) had progressive disease. The GP + E group had a significantly higher overall response rate (75% vs. 42.9%; P = 0.028), and median progression‐free survival (PFS) and overall survival (OS) of 19 and 76 months, respectively. In the GP only group, median PFS and OS were 16 and 29 months, respectively. PFS and OS were not significantly different between the groups. CONCLUSIONS: GP has moderate efficacy and could represent a suitable first‐line therapy for thymic carcinoma and thymoma. Chemotherapy combined with endostar could improve the overall response rate, but did not prolong PFS or OS. John Wiley & Sons Australia, Ltd 2018-11-09 2019-01 /pmc/articles/PMC6312837/ /pubmed/30411854 http://dx.doi.org/10.1111/1759-7714.12891 Text en © 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Wang, Yang Nie, Jun Dai, Ling Hu, Weiheng Chen, Xiaoling Han, Jindi Ma, Xiangjuan Tian, Guangming Han, Sen Long, Jieran Zhang, Ziran Fang, Jian Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma |
title | Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma |
title_full | Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma |
title_fullStr | Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma |
title_full_unstemmed | Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma |
title_short | Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma |
title_sort | efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312837/ https://www.ncbi.nlm.nih.gov/pubmed/30411854 http://dx.doi.org/10.1111/1759-7714.12891 |
work_keys_str_mv | AT wangyang efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma AT niejun efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma AT dailing efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma AT huweiheng efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma AT chenxiaoling efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma AT hanjindi efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma AT maxiangjuan efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma AT tianguangming efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma AT hansen efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma AT longjieran efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma AT zhangziran efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma AT fangjian efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma |